Show simple item record

dc.contributor.authorCherian, Jacob
dc.contributor.authorPuri, Ajit S.
dc.contributor.authorKan, Peter
dc.date2022-08-11T08:10:49.000
dc.date.accessioned2022-08-23T17:20:51Z
dc.date.available2022-08-23T17:20:51Z
dc.date.issued2019-09-26
dc.date.submitted2019-11-19
dc.identifier.citation<p>Neurosurgery. 2019 Sep 26. pii: nyz380. doi: 10.1093/neuros/nyz380. [Epub ahead of print] <a href="https://doi.org/10.1093/neuros/nyz380">Link to article on publisher's site</a></p>
dc.identifier.issn0148-396X (Linking)
dc.identifier.doi10.1093/neuros/nyz380
dc.identifier.pmid31557290
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48394
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractBACKGROUND: Though the Pipeline Embolization Device (Medtronic) is approved for use in adults 22 yr and older, the high efficacy and long-term durability of the device is attractive for treatment of intracranial aneurysms in younger patients who often have aneurysms less amenable to traditional endovascular treatments. OBJECTIVE: To report technical, angiographic, and clinical outcomes in patients aged 21 or below undergoing flow-diversion treatment for intracranial aneurysms. METHODS: Retrospective review across 16 institutions identified 39 patients aged 21 or below undergoing 46 treatment sessions with Pipeline Embolization Device placement between 2012 and 2018. A total of 50 intracranial aneurysms were treated. Details regarding patient demographics, aneurysm characteristics, treatment considerations, clinical outcomes, and aneurysm occlusion were obtained and analyzed in a multicenter database. RESULTS: A total of 70% of patients were male. Nonsaccular morphology was seen in half of identified aneurysms. Six aneurysms were giant, and five patients were treated acutely after ruptured presentation. Eight patients were younger than 10 yr of age. Complete aneurysm occlusion was seen in 74% of treated aneurysms. Three aneurysms (6%) were retreated. A total of 83% of patients had a modified Rankin Scale scores of < /=2 at last clinical follow-up. There were 2 early mortalities (4.3%) in the immediate postprocedure period because of rerupture of a treated ruptured aneurysm. No recanalization of a previously occluded aneurysm was observed. CONCLUSION: Flow-diversion treatment is a safe and effective treatment for intracranial aneurysms in patients younger than 22 yr. Rates of complete aneurysm occlusion and adverse events are comparable for rates seen in older patients.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31557290&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1093/neuros/nyz380
dc.subjectFlow diversion
dc.subjectIntracranial aneurysm
dc.subjectPediatric
dc.subjectangiogram
dc.subjectintracranial aneurysm
dc.subjectaneurysm
dc.subjectruptured aneurysm
dc.subjectfollow-up
dc.subjectpediatrics
dc.subjectrupture devices
dc.subjectmedical
dc.subjectdiversion procedure
dc.subjectendovascular procedures
dc.subjectfluid flow
dc.subjectAnalytical, Diagnostic and Therapeutic Techniques and Equipment
dc.subjectCardiovascular Diseases
dc.subjectNervous System Diseases
dc.subjectNeurology
dc.subjectPediatrics
dc.subjectRadiology
dc.subjectSurgery
dc.titleFlow Diversion for Treatment of Intracranial Aneurysms in Pediatric Patients: Multicenter Case Series
dc.typeJournal Article
dc.source.journaltitleNeurosurgery
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiology_pubs/504
dc.identifier.contextkey15820722
html.description.abstract<p>BACKGROUND: Though the Pipeline Embolization Device (Medtronic) is approved for use in adults 22 yr and older, the high efficacy and long-term durability of the device is attractive for treatment of intracranial aneurysms in younger patients who often have aneurysms less amenable to traditional endovascular treatments.</p> <p>OBJECTIVE: To report technical, angiographic, and clinical outcomes in patients aged 21 or below undergoing flow-diversion treatment for intracranial aneurysms.</p> <p>METHODS: Retrospective review across 16 institutions identified 39 patients aged 21 or below undergoing 46 treatment sessions with Pipeline Embolization Device placement between 2012 and 2018. A total of 50 intracranial aneurysms were treated. Details regarding patient demographics, aneurysm characteristics, treatment considerations, clinical outcomes, and aneurysm occlusion were obtained and analyzed in a multicenter database.</p> <p>RESULTS: A total of 70% of patients were male. Nonsaccular morphology was seen in half of identified aneurysms. Six aneurysms were giant, and five patients were treated acutely after ruptured presentation. Eight patients were younger than 10 yr of age. Complete aneurysm occlusion was seen in 74% of treated aneurysms. Three aneurysms (6%) were retreated. A total of 83% of patients had a modified Rankin Scale scores of < /=2 at last clinical follow-up. There were 2 early mortalities (4.3%) in the immediate postprocedure period because of rerupture of a treated ruptured aneurysm. No recanalization of a previously occluded aneurysm was observed.</p> <p>CONCLUSION: Flow-diversion treatment is a safe and effective treatment for intracranial aneurysms in patients younger than 22 yr. Rates of complete aneurysm occlusion and adverse events are comparable for rates seen in older patients.</p>
dc.identifier.submissionpathradiology_pubs/504
dc.contributor.departmentDepartment of Radiology


This item appears in the following Collection(s)

Show simple item record